Year To Quarter End Consolidated Statement Of Comprehensive Income

TAIKO PHARMACEUTICAL CO., LTD. - Filing #7270730

Concept 2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2024-01-01 to
2024-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
2023-01-01 to
2023-12-31
Year to quarter end consolidated statement of comprehensive income
Statement of comprehensive income
Profit (loss)
1,171,000,000 JPY
898,000,000 JPY
1,171,000,000 JPY
1,171,000,000 JPY
1,171,000,000 JPY
-3,724,000,000 JPY
-3,724,000,000 JPY
-3,611,000,000 JPY
-3,724,000,000 JPY
-3,724,000,000 JPY
Other comprehensive income
Valuation difference on available-for-sale securities
143,000,000 JPY
91,000,000 JPY
Foreign currency translation adjustment
105,000,000 JPY
53,000,000 JPY
Other comprehensive income
248,000,000 JPY
145,000,000 JPY
Comprehensive income
1,147,000,000 JPY
-3,466,000,000 JPY
Comprehensive income attributable to
Comprehensive income attributable to owners of parent
1,147,000,000 JPY
-3,466,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.